Meet and greet: SITC 2021

By Samantha Black, PhD, ScienceBoard editor in chief
January 7, 2022

The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health.

As part of our event coverage, the ScienceBoard team queried SITC exhibitors and produced these short videos to introduce our readers to individuals on the business side of science. The "Fun 5" is a meet-and-greet style series that features essential team members working behind the scenes at biotech and pharma companies who are fueling innovation.

In case you were wondering, as of December 2021, the bets favored self-cloaking viruses (24) to win out over regenerating bacteria (18)!

Find us at events to participate and keep track of the battle of bacteria versus viruses as we continue to update the stats in 2022.

Thank you to all of the vendors that participated in our coverage of SITC 2021:

  • Adaptive Biotechnologies
  • 10x Genomics
  • Adaptive Biotechnologies
  • Akoya
  • Axion Biosystems
  • Biognosys
  • BioLegend
  • Canopy Bio
  • ClearLight Bio
  • Crown Biosciences
  • Curiox Biosystems
  • GemPharmatech
  • GenScript
  • Iqvia
  • iRepertoire
  • Isoplexis
  • Leinco Technologies
  • Lonza
  • Lunaphore Technologies
  • Mabtech
  • Microba
  • NeoGenomics
  • Nexcelom
  • Replimune
  • Scale Ready

Battle royale: Self-cloaking virus vs. regenerating bacteria
Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human...
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer...
Where is the immunotherapy field headed after COVID-19?
WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired...
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help...

Copyright © 2022

Last Updated ka 1/7/2022 5:09:31 PM